missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD117/c-kit Antibody (CL1667), Novus Biologicals™
Mouse Monoclonal Antibody has been used in 1 publication
Brand: Novus Biologicals NBP2-34487
This item is not returnable.
View return policy
Description
CD117/c-kit Monoclonal specifically detects CD117/c-kit in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin.
Specifications
| CD117/c-kit | |
| Monoclonal | |
| Unconjugated | |
| P10721 | |
| KIT | |
| This antibody was developed against a recombinant protein corresponding to amino acids: VGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQ | |
| 0.1 mL | |
| Cancer, Cellular Markers, Cytokine Research, Hematopoietic Stem Cell Markers, Immunology, Innate Immunity, Mast Cell Markers, Mesenchymal Stem Cell Markers, Protein Kinase, Signal Transduction, Stem Cell Markers, Tyrosine Kinases | |
| 3815 | |
| Human | |
| Purified |
| Western Blot, Immunohistochemistry | |
| CL1667 | |
| Western Blot 1:500 - 1:1000, Immunohistochemistry 1:200 - 1:500, Immunohistochemistry-Paraffin 1:200 - 1:500 | |
| CD117, CD117 antigen, ckit, C-Kit, EC 2.7.10, EC 2.7.10.1, PBT, piebald trait, Proto-oncogene c-Kit, proto-oncogene tyrosine-protein kinase Kit, SCFRmast/stem cell growth factor receptor, soluble KIT variant 1, Tyrosine-protein kinase Kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein | |
| Mouse | |
| Protein A purified | |
| RUO | |
| Primary | |
| Specificity of antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins. | |
| Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
| IgG2a |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction